Crick — Clinical Intelligence Platform

Large-scale testing (Phase 3)Active Not RecruitingNCT04214067

What this trial is testing

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Who this might be right for

Endometrial Endometrioid AdenocarcinomaStage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

National Cancer Institute (NCI) 164

Results for “Uterine Endometrial Repair”

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

ALPINE: Maintenance Letrozole/Abemaciclib

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

CtDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Treatment of Intrauterine Adhesions and Its Distribution of Genital Tract Flora

Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome

Effects of Aspirin on Uterine Endometrial Repair Severe Intrauterine Adhesion

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Integrated Cancer Repository for Cancer Research

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Registry for Women Who Are At Risk Or May Have Lynch Syndrome

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers